Biontech: New hope for uterine cancer from 2026!
Biontech: New hope for uterine cancer from 2026!
Dewezet, Deutschland - Biontech, the German biotechnology company, plans to submit an important application for admission for a new cancer medication in the USA by the end of 2025. This innovative drug aims at the treatment of uterine cancer and relies on antibody-active ingredient conjugate in order to transport chemotherapy active ingredients precisely to cancer cells. The first desired oncological market registration should take place in 2026, such as Dewezet.de reported.
Clinical studies in the late phase 3 for several types of active ingredients that aim to aim at different types of cancer run. This development comes at a time when the company is also faced with financial challenges. In the first quarter of 2025, Biontech recorded a net loss of 415.8 million euros. For comparison: In the same period last year, the loss was 315.1 million euros. This happened with sales of 182.8 million euros, which was 187.6 million euros last year.financial situation and strategic goals
CFO Jens Holstein expressed that sales meet expectations and reflect the seasonal demand for COVID 19 vaccines. It was also announced that Ramón Zapata-Gomez, who previously worked at Novartis, will take over the position of the CFO on July 1, 2025. Holstein will retire at the end of June. For the entire 2025 financial year, Biontech expects sales to achieve between 1.7 and 2.2 billion euros, which is below the 2.75 billion euros of the previous year.
Expenditures for research and development increased to 525.6 million euros in the first quarter of 2025, compared to almost 508 million euros in the previous year. These investments are necessary to advance the clinical studies and to achieve long-term strategic goal: to become a leading biotech company with several oncological products by 2030, as well as ak-kurier.de confirmed
The plans of Biontech, especially in cancer research, mark a significant expansion of the company's portfolio and show its commitment to develop innovative therapies in order to improve the treatment standards in oncology. Also pharmacy-adhoc.de emphasizes how crucial these developments are for the future of biontech.
| Details | |
|---|---|
| Ort | Dewezet, Deutschland |
| Quellen | |